Ticker Details
Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
IPO Date:	October 5, 2001
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.99B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.19%
Avg Daily Range (30 D):	$0.36 | 1.51%
Avg Daily Range (90 D):	$0.33 | 1.42%

Institutional Daily Volume
Avg Daily Volume:	.86M
Avg Daily Volume (30 D):	.97M
Avg Daily Volume (90 D):	.95M

Trade Size
Avg Trade Size (Sh.):	147
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	2,453
Avg Institutional Trade:	$2.73M
Avg Institutional Trade (30 D):	$2.85M
Avg Institutional Trade (90 D):	$2.92M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.57M
Avg Closing Trade (30 D):	$4.84M
Avg Closing Trade (90 D):	$4.85M
Avg Closing Volume:	270.43K

News

Dec 31, 2025 @ 4:06 PM Catalyst Pharmaceuticals Executive Cashes Out 10,9... Source: Sara Appino

Nov 4, 2025 @ 6:31 AM Five-year data of AGAMREE® (vamorolone) in pati... Source: Santhera Pharmaceuticals

Nov 4, 2025 @ 6:31 AM Fünfjahresdaten zu AGAMREE® (Vamorolon) bei ... Source: Santhera Pharmaceuticals

Aug 26, 2025 @ 11:12 PM UPDATED- Catalyst Pharmaceuticals Announces Settle... Source: Catalyst Pharmaceuticals, Inc.

Mar 24, 2025 @ 6:00 AM Santhera to share latest on commercial rollout of ... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1.79	$.43	$.43
Diluted EPS	$1.72	$.42	$.41
Revenue	$578.2M	$148.39M	$146.56M
Gross Profit	$495.37M	$125.74M	$125.95M
Net Income / Loss	$217.56M	$52.78M	$52.11M
Operating Income / Loss	$258.78M	$66.27M	$66.3M
Cost of Revenue	$82.82M	$22.65M	$20.61M
Net Cash Flow	$247.56M	$37.09M	$135.25M
PE Ratio	14.06